| Consensus guidelines for the use and interpretation of angiogenesis assays P Nowak-Sliwinska, K Alitalo, E Allen, A Anisimov, AC Aplin, R Auerbach, ... Angiogenesis 21, 425-532, 2018 | 553 | 2018 |
| Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell–cell and cell–matrix contacts P Saharinen, L Eklund, J Miettinen, R Wirkkala, A Anisimov, M Winderlich, ... Nature cell biology 10 (5), 527-537, 2008 | 539 | 2008 |
| Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis Y Takeda, S Costa, E Delamarre, C Roncal, R Leite de Oliveira, ... Nature 479 (7371), 122-126, 2011 | 317 | 2011 |
| CCBE1 Enhances Lymphangiogenesis via A Disintegrin and Metalloprotease With Thrombospondin Motifs-3–Mediated Vascular Endothelial Growth Factor-C … M Jeltsch, SK Jha, D Tvorogov, A Anisimov, VM Leppänen, T Holopainen, ... Circulation 129 (19), 1962-1971, 2014 | 258 | 2014 |
| Tie1 controls angiopoietin function in vascular remodeling and inflammation EA Korhonen, A Lampinen, H Giri, A Anisimov, M Kim, B Allen, S Fang, ... The Journal of clinical investigation 126 (9), 3495-3510, 2016 | 239 | 2016 |
| Effects of angiopoietin-2-blocking antibody on endothelial cell–cell junctions and lung metastasis T Holopainen, P Saharinen, G D’Amico, A Lampinen, L Eklund, ... Journal of the National Cancer Institute 104 (6), 461-475, 2012 | 235 | 2012 |
| VEGF receptor 2/‐3 heterodimers detected in situ by proximity ligation on angiogenic sprouts I Nilsson, F Bahram, X Li, L Gualandi, S Koch, M Jarvius, O Söderberg, ... The EMBO journal 29 (8), 1377-1388, 2010 | 225 | 2010 |
| Structural determinants of growth factor binding and specificity by VEGF receptor 2 VM Leppänen, AE Prota, M Jeltsch, A Anisimov, N Kalkkinen, T Strandin, ... Proceedings of the National Academy of Sciences 107 (6), 2425-2430, 2010 | 220 | 2010 |
| Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization D Tvorogov, A Anisimov, W Zheng, VM Leppänen, T Tammela, ... Cancer cell 18 (6), 630-640, 2010 | 178 | 2010 |
| VEGF‐B‐induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart R Kivelä, M Bry, MR Robciuc, M Räsänen, M Taavitsainen, JMU Silvola, ... EMBO molecular medicine 6 (3), 307-321, 2014 | 174 | 2014 |
| Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span M Grunewald, S Kumar, H Sharife, E Volinsky, A Gileles-Hillel, T Licht, ... Science 373 (6554), eabc8479, 2021 | 169 | 2021 |
| Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation M Bry, R Kivelä, T Holopainen, A Anisimov, T Tammela, J Soronen, ... Circulation 122 (17), 1725-1733, 2010 | 156 | 2010 |
| Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor W Zheng, T Tammela, M Yamamoto, A Anisimov, T Holopainen, ... Blood, The Journal of the American Society of Hematology 118 (4), 1154-1162, 2011 | 138 | 2011 |
| Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity RL de Oliveira, S Deschoemaeker, AT Henze, K Debackere, ... Cancer cell 22 (2), 263-277, 2012 | 137 | 2012 |
| Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD HM Bui, D Enis, MR Robciuc, HJ Nurmi, J Cohen, M Chen, Y Yang, ... The Journal of clinical investigation 126 (6), 2167-2180, 2016 | 135 | 2016 |
| Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2–implications for microvascular inflammation and hypercoagulopathy in COVID-19 patients L He, MA Mäe, Y Sun, L Muhl, K Nahar, EV Liébanas, MJ Fagerlund, ... BioRxiv, 2020.05. 11.088500, 2020 | 132 | 2020 |
| Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle A Anisimov, A Alitalo, P Korpisalo, J Soronen, S Kaijalainen, ... Circulation research 104 (11), 1302-1312, 2009 | 122 | 2009 |
| Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation VM Leppänen, D Tvorogov, K Kisko, AE Prota, M Jeltsch, A Anisimov, ... Proceedings of the National Academy of Sciences 110 (32), 12960-12965, 2013 | 119 | 2013 |
| Structural determinants of vascular endothelial growth factor-D receptor binding and specificity VM Leppänen, M Jeltsch, A Anisimov, D Tvorogov, K Aho, N Kalkkinen, ... Blood, The Journal of the American Society of Hematology 117 (5), 1507-1515, 2011 | 106 | 2011 |
| Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy G D’Amico, EA Korhonen, A Anisimov, G Zarkada, T Holopainen, ... The Journal of clinical investigation 124 (2), 824-834, 2014 | 94 | 2014 |
